Screener
Twist Bioscience Corporation TWST Debt Issuance Proceeds
Debt Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Twist Bioscience Corporation in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt.
The source filing: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001581280-26-000040
| (in thousands) | Six months ended March 31, 2026 | Six months ended March 31, 2025 |
|---|---|---|
| Net cash used in investing activities | $(22,639) | $(2,962) |
| Financing activities | ||
| Proceeds from exercise of stock options | $2,089 | $3,722 |
| Proceeds from the issuance of liability related to sale of future revenue | — | 15,000 |
| Proceeds from issuance under employee stock purchase plan | 2,357 | 2,429 |
| Repurchases of common stock for income tax withholding | (10) | (11) |
| Net cash provided by financing activities | $4,436 | $21,140 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | $3 | $51 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Twist Bioscience Corporation's debt issuance proceeds?
- Twist Bioscience Corporation (TWST) reported debt issuance proceeds of $0 in Q1 2026.
- What does debt issuance proceeds mean?
- Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.
Ask your AI about Twist Bioscience Corporation's debt issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude